# Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

> **NCT01590199** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** RAD001
- **DRUG:** SOM230

## Key facts

- **NCT ID:** NCT01590199
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-18
- **Primary completion:** 2018-09-11
- **Final completion:** 2018-09-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01590199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01590199, "Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01590199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*